Nanotrap® Particles and SARS-CoV-2
The Nanotrap® Virus Capture Kit improves the performance of your downstream analytical methods (e.g., PCR, Western blot, NGS, protein assays, infectivity assays) by concentrating whole virus from large volumes (up to 10 mL) of complex biological fluids into a significantly smaller volume (less than 100 µL).
New preprint demonstrates a rapid and versatile method for improving detection of SARS-CoV-2.
Nanotrap® Particles capture and concentrate the following respiratory viruses: influenza A H1N1 (1), Influenza A H3N2 (1), influenza B (1), respiratory syncytial virus A2001/3-12 strain (1), coronavirus strain 229E (1), coronavirus strain OC43 (2), and SARS-CoV-2 (3)(4).
Compatible with most nucleic acid extraction kits.
Reduce sample processing time by 2- to 3-fold by eliminating commercial extraction kit.
Methods developed for viral transport medium and saliva.
Enables pooled patient sample testing with methods developed for sample volumes up to 10 mL.
Eliminate false negatives. Nanotrap particles enabled the identification of SARS-CoV-2 RNA in 9 out of 32 diagnostic remnant samples that had previously tested negative for the virus.
Increase assay sensitivity by capturing and concentrating low abundance viruses. Nanotrap particles improved the real-time RT-PCR signal in low viral load diagnostic remnant samples by an average of 3.1 Ct values.
If you have an idea for a collaboration using the Nanotrap® Virus Capture Kit in your COVID-19 project, please contact COVID19@ceresnano.com.